drugset / Trial / NCT05963932

A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants

NCT05963932

Phase 1 Completed 60 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the impact of the BMS-986419 new immediate release (IR) tablet formulation compared to the current enteric (DR) capsule formulation, and to assess the effect of food on the drug levels of the IR tablet formulation in healthy adult participants.

Timeline

Start
2023-08-08
Primary completion
2023-10-17
Completion
2023-10-17

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986419 Unknown

Indications

No indication recorded.